期刊
BONE MARROW TRANSPLANTATION
卷 49, 期 5, 页码 664-670出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2013.235
关键词
BK virus; hemorrhagic cystitis; allogeneic hematopoietic SCT; PCR; cidofovir
BK virus (BKV) reactivation has been increasingly associated with the occurrence of late-onset hemorrhagic cystitis (HC) after allogeneic hematopoietic SCT (allo-HSCT) resulting in morbidity and sometimes mortality. We investigated the incidence, risk factors and outcome of BKV-HC in 323 consecutive adult patients undergoing allo-HSCT over a 5-year period. BK viremia values for HC staging were evaluated, as well as the medico-economic impact of the complication. Forty-three patients developed BKV-HC. In univariate analysis, young age (P = 0.028), unrelated donor (P = 0.0178), stem cell source (P = 0.0001), HLA mismatching (P = 0.0022) and BU in conditioning regimen (P = 0.01) were associated with a higher risk of developing BKV-HC. In multivariate analysis, patients receiving cord blood units (CBUs) (P = 0.0005) and peripheral blood stem cells (P = 0.011) represented high-risk subgroups for developing BKV-HC. BK viremia was directly correlated to HC severity (P = 0.011) with a 3 to 6-log peak being likely associated with grades 3 or 4 HC. No correlation was found between BKV-HC and acute graft versus host disease or mortality rate. Patients with BKV-HC required a significantly longer duration of hospitalization (P < 0.0001), more RBC (P = 0.0003) and platelet transfusions (P < 0.0001). Over the 5-year study period, the financial cost of the complication was evaluated at is an element of 2 376 076 ($ 3 088 899). Strategies to prevent the occurrence of late-onset BKV-HC after allo-HSCT are urgently needed, especially in CBU and peripheral blood stem cell recipients. BK viremia correlates with the severity of the disease. Prospective studies are required to test prophylactic approaches.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据